U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282743) titled 'Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus' on Dec. 05.
Brief Summary: This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from bas...